Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Sep 21;9(10):ofac477.
doi: 10.1093/ofid/ofac477. eCollection 2022 Oct.

Hepatitis C Virus Coinfection in People With Human Immunodeficiency Virus in Iran: A Systematic Review and Meta-Analysis

Affiliations

Hepatitis C Virus Coinfection in People With Human Immunodeficiency Virus in Iran: A Systematic Review and Meta-Analysis

Seyedeh-Kiana Razavi-Amoli et al. Open Forum Infect Dis. .

Abstract

Background: Hepatitis C virus (HCV) coinfection is associated with higher mortality and morbidity in people with human immunodeficiency virus (PWH).

Methods: We aimed to characterize the epidemiology and factors associated with HCV coinfection among PWH in Iran. In this systematic review, we searched 3 English databases (MEDLINE, SCOPUS, Embase) and 2 Farsi databases (Scientific Information Database and Magiran) for studies that measured the prevalence of HCV coinfection among PWH, published between 2000 and January 1, 2021. We included studies with a minimum sample size of 5 PWH. Reviews, editorials, conference abstracts, theses, studies with no relevant data, and unclear serological assays were excluded.

Results: We summarized the HCV coinfection prevalence by random-effect meta-analysis and assessed the sources of heterogeneity by a meta-regression model. Of the 858 records identified, 69 eligible studies with 12 996 PWH were included. Overall, HCV coinfection prevalence was 64% (95% confidence interval [CI], 58-69). The prevalence was higher among older (mean age ≥35 years) PWH (69%; 95% CI, 64-74) and PWH who inject drugs (77%; 95% CI, 71-82). Furthermore, we found that coinfection was higher among studies conducted between 2000 and 2014 (67%; 95% CI, 59-75) versus 2015-2020 (57%; 95% CI, 50-64).

Conclusions: The prevalence of HCV coinfection is high in Iranian PWH, with significant geographical variations. Hepatitis C virus screening and treatment among PWH are warranted to avoid the future burden of HCV-related liver damage, cancer, and mortality.

Keywords: Iran; coinfection; hepatitis C; human immunodeficiency virus; people with HIV.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Flowchart of included studies. HCV, hepatitis C virus; HIV, human immunodeficiency virus; SID, Scientific Information Database.
Figure 2.
Figure 2.
Prevalence of human immunodeficiency virus (HIV)-hepatitis C virus (HCV) coinfection in people with HIV in Iran. CI, confidence interval; ES, effect size.
Figure 3.
Figure 3.
(A) Prevalence of human immunodeficiency virus (HIV)-hepatitis C virus (HCV) coinfection in people with HIV with mean age less than 35 years (A) and equal to or more than 35 years (B). CI, confidence interval; ES, effect size.
Figure 4.
Figure 4.
Prevalence of hepatitis C virus (HCV) coinfection in people with human immunodeficiency virus (HIV) in years 2000–2014 (A) and 2015–2020 (B). CI, confidence interval; ES, effect size.
Figure 5.
Figure 5.
Prevalence of hepatitis C virus (HCV) coinfection among people with human immunodeficiency virus (HIV) with injection drug user (IDU) proportion less than 75% (A) and equal to or more than 75% (B). CI, confidence interval; ES, effect size.
Figure 6.
Figure 6.
Prevalence of hepatitis C virus (HCV) coinfection in people with human immunodeficiency virus (HIV) in Southwest (A), South-Central (B), Northwest (C), East (D), and North-Cental Iran (E). CI, confidence interval; ES, effect size.

Similar articles

References

    1. Arum C, Fraser H, Artenie AA, et al. . Homelessness, unstable housing, and risk of HIV and hepatitis C virus acquisition among people who inject drugs: a systematic review and meta-analysis. Lancet Public Health 2021; 6:e309–23. - PMC - PubMed
    1. Available at: https://www.who.int/en/news-room/fact-sheets/detail/hepatitis-c. Accessed.
    1. Available at: https://www.unaids.org/en. Accessed.
    1. Seyedalinaghi SA, Taj L, Mazaheri-Tehrani E, et al. . HIV in Iran: onset, responses, and future directions. AIDS 2021; 35:529–42. - PMC - PubMed
    1. Available at: https://www.unaids.org/en/regionscountries/countries/islamicrepublicofiran. Accessed.